Everolimus in every day practice of metastatic renal cell carcinoma therapy – one center experience
Journal Title: OncoReview - Year 2016, Vol 6, Issue 3
Abstract
Introduction: Everolimus is a selective mTOR inhibitor which received approval for treatment of advanced renal cell carcinoma (mRCC) after progression on or after treatment with VEGF-targeted therapy. The aim of this study was to evaluate the efficiency and toxicity profile of everolimus in second line therapy of mRCC. The authors also assessed the impact of clinicopathological factors on the effectiveness of everolimus.Methods: The retrospective analysis was conducted on the medical records of 33 mRCC patients who were treated with everolimus in second line therapy after progression on interferon or tyrosine kinase inhibitors (sunitinib or pazopanib) during the years 2010–2016.Results: Median time of treatment with everolimus was 4 months (range from 1 to 58 months). Median progression free survival was 4 months and overall survival (OS) was 11 months. The best response (PR + CR + SD) was reported in 57% of patients. Toxicity in grade 3–4 was reported in 9 (27%) of patients. Clinicopathological factors associated with progression during everolimus therapy were: smoking and alcohol abuse (p = 0.029), higher Furman grade (p = 0.166), tumor necrosis (p = 0.383), fat tissue infiltration (p = 0.040), lymph node (p = 0.193) and adrenal metastases (p = 0.067). Factors which increase the risk of everolimus toxicity were worse performance status (p = 0.333) and more advanced disease at the beginning (lymph nodes metastases, p = 0.05) and higher Furman grade (p = 0.04).Conclusions: Cigarettes use and/or alcohol abuse, adrenal metastases, fat tissue had significantly negative influence on survival. Grade 3–4 toxicity were reported more frequently in patients with worse performance status and more advanced disease at the time of diagnosis.
Authors and Affiliations
Joanna Huszno, Elżbieta Nowara
Keywords
Related Articles
- EP ID EP80369
- DOI -
- Views 209
- Downloads 0
Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT)...
Childhood Cancer Survivorship Late Cardiotoxicity, and CV Prevention
Safety and efficacy of liposomal doxorubicin in a patient treated for metastatic breast cancer
Breast cancer is the most common malignancy among women in Poland and all over the world. Despite the development of modern therapies, cytostatics still play one of the main roles in treatment of this disease. Classic an...
Remote consequences of polychemical and radiation therapy: cardiac valve disease complicated by infective endocarditis. Diagnostic and management problems
One of the quite frequent long-term effects of radiation therapy of malignant tumors, such as breast cancer and Hodgkin’s lymphoma primarily, when the irradiation of the mediastinum is performed, is the development of ra...
The role of vena cava inferior filters in the prevention of venous thromboembolism prior to oncological surgeries
Venous thromboembolism represents one of the most important causes of complications and mortality in cancer patients. The therapy in this group of patients is mainly focused on adequate anticoagulant prophylaxis. In diff...